LobbyingNuvation Bio lobbying by quarter
Nuvation Bio NUVB's latest lobbying report covers Q2 2026, at $80K. Its first report covers Q1 2026; the issues it reports most are Health Issues.
Nuvation BioNUVB
- Latest quarter
- $80K
- Q2 2026 · 1 reports
- Last 12 months
- $110K
- Last 2 quarters
- vs last quarter
- +166.7%
- Q2 2026 against the quarter before
- First report
- Q1 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2026 | $30K | 1 |
| Q2 2026 | $80K | 1 |
Policy issues the reports name
- Health issues2 reports
A report that names several issues counts once for each.
Who was lobbied
- Food & Drug Administration (FDA)1 reports
- HOUSE OF REPRESENTATIVES1 reports
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| BGR Government Affairs | $110K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | BGR Government Affairs | $80K |
| 04/20for Q1 | BGR Government Affairs | $30K |
| 04/10for Q1 | BGR Government Affairs | Under $5,000 |